In This Article:
As the U.S. stock market reacts to recent developments in tariffs and corporate earnings, investors are on the lookout for opportunities that may not be immediately apparent in larger indices. Penny stocks, a term often associated with speculative investments, represent an intriguing segment of the market where smaller or newer companies can offer potential growth at accessible price points. Despite their vintage label, these stocks can provide substantial value when backed by strong financials and fundamentals, making them worthy of attention for those seeking hidden gems in today's economic landscape.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.8975 | $6.46M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $121.65M | ★★★★★★ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.2651 | $10.4M | ★★★★★★ |
Imperial Petroleum (NasdaqCM:IMPP) | $2.91 | $89.18M | ★★★★★★ |
Permianville Royalty Trust (NYSE:PVL) | $1.45 | $48.18M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
BTCS (NasdaqCM:BTCS) | $2.94 | $52.92M | ★★★★★★ |
Smith Micro Software (NasdaqCM:SMSI) | $1.24 | $22.53M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.9305 | $85.11M | ★★★★★☆ |
SideChannel (OTCPK:SDCH) | $0.04 | $9.02M | ★★★★★★ |
Click here to see the full list of 715 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
FibroBiologics
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: FibroBiologics, Inc. is a cell therapy and regenerative medicine company with a market cap of $56.49 million.
Operations: FibroBiologics, Inc. currently does not report any revenue segments.
Market Cap: $56.49M
FibroBiologics, Inc., with a market cap of US$56.49 million, is a pre-revenue company in the biotech sector. Recent activities include filing multiple shelf registrations, notably closing one for US$93.77 million and entering into equity agreements to bolster its cash position. Despite these capital-raising efforts, the company remains unprofitable with increasing losses over five years at 51% annually and forecasts suggest further earnings decline by 16.7% per year over the next three years. FibroBiologics' short-term assets exceed liabilities, but its volatile share price reflects ongoing financial instability as it navigates early-stage development challenges.
-
Click to explore a detailed breakdown of our findings in FibroBiologics' financial health report.
-
Understand FibroBiologics' earnings outlook by examining our growth report.
Sypris Solutions
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Sypris Solutions, Inc. operates in North America and Mexico, providing truck components, oil and gas pipeline components, and aerospace and defense electronics, with a market cap of $49.22 million.